A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression.

The AAA-ATPase TRIP13 drives multiple myeloma (MM) progression. Here we present the crystal structure of wild-type human TRIP13 at a resolution of 2.6 Å. A small molecule inhibitor targeting TRIP13 was identified based on the crystal structure. The inhibitor, designated DCZ0415, was confirmed to bind TRIP13 using pull-down, nuclear magnetic resonance spectroscopy, and surface plasmon resonance binding assays. DCZ0415 induced anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients. The inhibitor impaired nonhomologous end joining repair and inhibited NF-κB activity. Moreover, combining DCZ0415 with the MM chemotherapeutic melphalan or the HDAC inhibitor panobinostat induced synergistic anti-myeloma activity. Therefore, targeting TRIP13 may be an effective therapeutic strategy for MM, particularly refractory or relapsed MM.

[1]  Weiliang Zhu,et al.  DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma , 2018, Acta biochimica et biophysica Sinica.

[2]  Weiliang Zhu,et al.  Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma , 2017, Theranostics.

[3]  F. Herzog,et al.  The AAA+ ATPase TRIP13 remodels HORMA domains through N‐terminal engagement and unfolding , 2017, The EMBO journal.

[4]  M. Boccadoro,et al.  Melphalan hydrochloride for the treatment of multiple myeloma , 2017, Expert opinion on pharmacotherapy.

[5]  Nisha S Joseph,et al.  High‐risk Multiple Myeloma: Definition and Management , 2017, Clinical lymphoma, myeloma & leukemia.

[6]  S. Seal,et al.  Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation , 2017, Nature Genetics.

[7]  Weiliang Zhu,et al.  TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma , 2017, Oncotarget.

[8]  D. Landau,et al.  Genomic complexity of multiple myeloma and its clinical implications , 2017, Nature Reviews Clinical Oncology.

[9]  S. Manon,et al.  A brewing understanding of the regulation of Bax function by Bcl-xL and Bcl-2 , 2017, Mechanisms of Ageing and Development.

[10]  Wang Dazhi,et al.  Elevated expression of thyroid hormone receptor-interacting protein 13 drives tumorigenesis and affects clinical outcome. , 2017, Biomarkers in medicine.

[11]  S. Schreiber,et al.  Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma , 2016, Proceedings of the National Academy of Sciences.

[12]  J. Diehl,et al.  Cyclin D1, cancer progression, and opportunities in cancer treatment , 2016, Journal of Molecular Medicine.

[13]  M. Beksac,et al.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. , 2014, The Lancet. Oncology.

[14]  S. Varambally,et al.  TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer , 2014, Nature Communications.

[15]  David Ryan Koes,et al.  Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking Exercise , 2013, J. Chem. Inf. Model..

[16]  A. De,et al.  An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression , 2012, Cell.

[17]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[18]  N. Becker.  Epidemiology of multiple myeloma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[19]  S. Keeney,et al.  Mouse TRIP13/PCH2 Is Required for Recombination and Normal Higher-Order Chromosome Structure during Meiosis , 2010, PLoS genetics.

[20]  M. Lieber,et al.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. , 2010, Annual review of biochemistry.

[21]  L. Staudt.  Oncogenic activation of NF-kappaB. , 2010, Cold Spring Harbor perspectives in biology.

[22]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[23]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[24]  A. Seluanov,et al.  Comparison of nonhomologous end joining and homologous recombination in human cells. , 2008, DNA repair.

[25]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[26]  J. Schimenti,et al.  Mouse Pachytene Checkpoint 2 (Trip13) Is Required for Completing Meiotic Recombination but Not Synapsis , 2007, PLoS genetics.

[27]  Kenneth C Anderson,et al.  Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. , 2007, Experimental hematology.

[28]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[29]  E. Holler,et al.  Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. , 2007, Experimental hematology.

[30]  Wladek Minor,et al.  HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.

[31]  A. Dernburg,et al.  A Conserved Checkpoint Monitors Meiotic Chromosome Synapsis in Caenorhabditis elegans , 2005, Science.

[32]  A. Weaver,et al.  A Review of Research on Chaplains and Community-Based Clergy in the Journal of the American Medical Association, Lancet, and the New England Journal of Medicine: 1998–2000 , 2004, The journal of pastoral care & counseling : JPCC.

[33]  Michael M. Murphy,et al.  ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.

[34]  P. Richardson,et al.  The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications , 2001, Oncogene.

[35]  K. Khanna,et al.  DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.

[36]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[37]  T. Lindahl,et al.  Repair of endogenous DNA damage. , 2000, Cold Spring Harbor symposia on quantitative biology.

[38]  G. Roeder,et al.  Pch2 Links Chromatin Silencing to Meiotic Checkpoint Control , 1999, Cell.

[39]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[40]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.